您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 意大利药房
产地国家: 意大利
所属类别: 影响血液及造血系统药物->抗血小板凝聚药
处方药:保健药品
包装规格: 200毫克/片 30片/盒
计价单位:
   
生产厂家英文名:
RANBAXY ITALIA SpA
该药品相关信息网址1:
http://www.drugcore.com/bencandy.php?fid=46&id=36891
原产地英文商品名:
Indobufene Ranb 200mg 30 Tablets.
原产地英文药品名:
Indobufen
中文参考商品译名:
Indobufene Ranb 200毫克/片 30片/盒
中文参考药品译名:
吲哚布芬
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Cerebral vascular disease
英文适应病症2:
Ischemic heart
英文适应病症3:
Atherosclerotic peripheral arterial disease
英文适应病症4:
Venous thrombosis
英文适应病症5:
Dyslipidemia
临床试验期:
完成
中文适应病症参考翻译1:
脑血管疾病
中文适应病症参考翻译2:
缺血性心脏
中文适应病症参考翻译3:
脉粥样硬化的外周动脉疾病
中文适应病症参考翻译4:
静脉血栓形成
中文适应病症参考翻译5:
血脂异常
药品信息:

---------------------------------------------------------------
部分中文Indobufene Ranb处方资料(仅供参考)

【药理与适用症】: 吲哚布芬可抑制引起血小板激活的一些因子(如ADP、5-HT、血小板因子4、β—小板球蛋白等)的释放以及影响花生四烯酸代谢而抗血小板聚集,但不影响PGI2的血浓度。对血液凝固的各种参数无影响,但能中等度地延长出血时间,停药后即可恢复。 口服后吸收迅速,血浆浓度达峰时间2小时;t1/2为8小时;与血浆蛋白结合率为99%。 用于动脉硬化所致的缺血性心、脑血管和周围血管疾病、静脉血栓形成、血酯代谢障碍等;也可用于体外循环手术时防止血栓形成。

【注意事项】: 偶有上腹不适、腹胀、胃肠道出血和鼻衄。有时出现过敏反应(荨麻疹)。禁用于有出血性疾病、妊娠及哺乳妇。

【用法与用量】: 每日剂量200—400mg,分2次口服或肌注或静注。老人及肾功能不全者宜减半。

【包装】: 片剂:每片200mg。注射液:每支200mg(2ml)。

NAME INDOBUFENE RAN * 200mg 30cpr

COMPANY Ranbaxy Italy S.p.A.

CLASS C

RECIPE RR - a medicinal product subject to medical prescription

ATC B01AC10 Indobufene

ACTIVE indobufene ( DC.IT )

GROUP Therap. antiplatelet

TYPE Indobufene

VALIDITY ' 30 months

THERAPEUTIC INDICATIONS

antiplatelet treatment in pathological conditions where hyperactivity or platelet activation may play a key role in the pathogenesis of thrombosis , such as : ischemic heart and cerebral vascular disease , atherosclerotic peripheral arterial disease , venous thrombosis , dyslipidemia and diabetes. Prevention of activation of thrombogenesis during extracorporeal circulation (hemodialysis )

DOSAGE AND ADMINISTRATION

the daily dosage is generally between 200 and 400 mg orally in 2 doses . The lower dose ( 200 mg / day ) is particularly suitable for long-term treatments . In the treatment of elderly patients, dosage should be carefully determined by the physician must evaluate a possible reduction of the dosages indicated above. In patients older than 65 years , the recommended dose is between 100 and 200 mg / day. E ' recommended taking the drug after meals. In the prevention of thrombogenesis during extracorporeal circulation (hemodialysis ) indobufene dose depends on the condition of the patient to the physician's judgment may be given 100 mg orally before each dialysis session . Renal impairment : In subjects with renal impairment is appropriate dose reductions in relation to the degree of renal function. As an indication, we suggest the following scheme: CrCl > 80 ml ​​/ min: 100-200 mg 2 times a day CrCl = 40-80 ml ​​/ min: 100 mg / day - 100 mg 2 times a day, creatinine clearance <40 ml / min: 100 mg every other day - 100 mg / day

调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com